We showed that neurodegeneration continued in RRMS patients under ALZ treatment, but it appeared to be limited to BPF and GM, and more pronounced in patients with disease activity. Our data suggest that patients who respond to ALZ treatment show signs of remyelination. OCT and SyMRI have potential to quantify measures of neurodegeneration that is affected by treatment intervention in RRMS.
Keyphrases
- multiple sclerosis
- disease activity
- rheumatoid arthritis
- systemic lupus erythematosus
- end stage renal disease
- randomized controlled trial
- newly diagnosed
- chronic kidney disease
- ejection fraction
- optical coherence tomography
- rheumatoid arthritis patients
- risk assessment
- combination therapy
- climate change
- diabetic retinopathy
- peritoneal dialysis
- big data